Subscribe
shutterstock_547487782_fabioberti
fabioberti / Shutterstock.com
12 February 2019Asia

Pharma group asks USTR to drop India from watch list

The lobby group for India’s pharma industry has asked the  US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York